Recommended

Sarepta’s DMD drug Elevidys issued FDA label update
Rare disease gene therapy granted European first approval
Johnson & Johnson agrees $3bn oncology acquisition
European Commission grants EU first for J&J’s Simponi biosimilar
Researchers validate approach that supports animal-based pyrogen test replacement
ON DEMAND webinar: automating QC testing for radiopharmaceutical production
Insmed secures EU approval for Brinsupri (brensocatib)
Moderna invests over $140m to onshore mRNA medicine manufacturing in US
news

Skin preparation electrode gel recalled due to infection risk to patients

0
SHARES

Mavidon has recalled LemonPrep, PediaPrep, Wave Prep and Cardio Prep due to the products being potentially contaminated with Burkholderia cepacia.

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has announced a recall of all lots of LemonPrep, PediaPrep, Wave Prep and Cardio Prep. This is due to these gel products, manufactured by Mavidon, potentially being be contaminated with the microorganism Burkholderia cepacia leading to an infection risk to patients.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The manufacturer identified an issue at its manufacturing facility which means products are potentially contaminated with B. cepacia, a drug-resistant microorganism, the agency said. The company is now recalling all gel products made at this site that use the affected production method.

The agency has advised that all of those responsible for the use of these devices should identify and quarantine all lots of the affected products in its organisation, using the manufacturer’s field safety notice and that if they are the affected products, fill in the recall form in the FSN and return it to the manufacturer.

It has also advised that any suspected or actual adverse events involving these devices should be reported through the local incident reporting system and/or the national incident reporting authority as appropriate. Reports should also be made directly to manufacturers if local or national systems do not.

The agency has said the aim is to have these actions complete by 4 March 2020.

More information, including manufacturer contacts and distribution lists, can be found here. 

Share via
Share via